Is MindImmune Therapeutics, Inc. a real, registered company?
MindImmune Therapeutics, Inc. is a registered filer with the SEC (CIK 1792522) and has filed since 2025-12-05. 2 filings are on record, the latest on 2026-03-05.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has MindImmune Therapeutics, Inc. raised?
Its new offerings report $10.20M sold across 1 offering, as its own filings state.
Run the free check on MindImmune Therapeutics, Inc. →
KINGSTON, RHODE ISLAND
Pharmaceuticals
2
$10.20M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-03-05 | Amendment first sale 2025-11-24 | $15.22M | $17.01M | SEC filing |
| 2025-12-05 | New offering first sale 2025-11-24 | $10.20M | $12M | SEC filing |
Keep reading
More on MindImmune Therapeutics, Inc. and the records around it.
MindImmune Therapeutics, Inc. elsewhere on the record
- Form D filing Dec 2025
Watch MindImmune Therapeutics, Inc.
Get an email when MindImmune Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with MindImmune Therapeutics, Inc.?
Who to contact
- Isaac Stoner — CEO
- Bradley Margus — Director
- Christopher O'Donnell — Director
- Reetika Bhardwaj — Director
- Round: Form D/A (amended) filed 2026-03-05
- Amount sold: $15.22M
- Industry: Pharmaceuticals
- Based: KINGSTON, RHODE ISLAND
People listed
- Isaac Stoner — CEO
- Bradley Margus — Director
- Christopher O'Donnell — Director
- Reetika Bhardwaj — Director
- Filing: Form D/A (amended) filed 2026-03-05
- Amount sold: $15.22M
- Industry group: Pharmaceuticals
- Based: KINGSTON, RHODE ISLAND
- Entity type: Corporation
We'll show it in your MentionFox inbox when MindImmune Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch MindImmune Therapeutics, Inc. →Want the whole picture on MindImmune Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on MindImmune Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MindImmune Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from MindImmune Therapeutics, Inc.'s own filings with the SEC. The people those filings name are on the team page.